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Background: Macrophages, the key component of the tumor microenvironment, are differentiated mononuclear
phagocyte lineage cells that are characterized by specific phenotypic characteristics that have been implicated in
tumor growth, angiogenesis, and invasion. CX3CR1, the chemoattractant cytokine CX3CL1 receptor, plays an
important role in modulating inflammatory responses, including monocyte homeostasis and macrophage
phenotype and function. However, the role of CX3CR1 in the regulation of the tumor inflammatory
microenvironment is not fully understood.
Methods: Using in vivo hepatic metastasis model, human colon carcinoma specimens, immunohistochemical
staining, TUNEL staining, flow cytometry analysis, Western blotting assay and co-culture in three-dimensional
peptide gel, we determined the effects of CX3CR1 on angiogenic macrophage survival and tumor metastasis.
Results: In this study, we found that CX3CR1 was expressed in human colon carcinomas in a histologic grade- and
stage-dependent manner, and CX3CR1 upregulation in TAMs was correlated with poor prognosis. Furthermore, we
showed that in a microenvironment lacking CX3CR1, the liver metastasis of colon cancer cells was significantly
inhibited. The underlying mechanism is associated with decrease accumulation of angiogenic macrophages that
can be partly attributed to increased apoptosis in the tumor microenvironment, thus leading to impaired tumor
angiogenesis in the liver and suppressed tumor metastasis.
Conclusions: Our results suggest a role of CX3CR1 in angiogenic macrophage survival in the tumor
microenvironment contributing to tumor metastasis.
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Tumors exhibit a complex cellular ecology that estab-
lishes their malignant potential. In addition to genetic
complexity, it has become increasingly apparent that the
tumor inflammatory microenvironment plays an active
role in promoting all stages of tumor progression [1-3].
Tumor ecosystems contain innate immune cells, the
most abundant of which are macrophages. Although the
original hypotheses proposed that macrophages are
involved in antitumor immunity, there is substantial
clinical and experimental evidence suggesting that tumor-* Correspondence: jdu@bcm.edu
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reproduction in any medium, provided the orassociated macrophages (TAMs) enhance tumor progres-
sion to malignancy in the majority of cases [4,5]. The
tumor-promoting functions of macrophages include sup-
porting tumor-associated angiogenesis, promoting tumor
cell invasion and migration, and suppressing antitumor
immune responses [6]. Accumulating evidence suggests
that tumor initiation, progression, and metastasis are af-
fected by dynamic changes in the phenotypes of macro-
phages, and that defined subpopulations of macrophages
are responsible for these tumor-promoting activities. In-
flammation and angiogenesis are the hallmarks of cancer.
Infiltration of TAMs is associated with a poor prognosis
[7], and studies have shown that not only their numbers
but also their phenotype regulate tumor progression.
However, the regulatory mechanisms of the phenotype
and function of TAMs remain elusive.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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attractant cytokines receptor, regulates the TAMs subtypes
in the tumor microenvironment, for several reasons. First,
CX3CR1 is primarily expressed on circulating monocytes,
tissue macrophages, and tissue dendritic cell populations
but is also expressed on T cell and natural killer cell sub-
sets [8]. Second, it is generally accepted that the surface
molecule CX3CR1 can be used to identify monocyte sub-
sets owing to its differential expression [9,10]. Third,
CX3CR1 and its ligand help control the migration and re-
cruitment of immune effector cells in numerous inflam-
matory diseases and may play a role in cancer progression,
immune evasion, and metastasis [8,11,12]. Fourth, increas-
ing evidence indicates that CX3CR1 is required for mono-
cyte homeostasis and differentiation and regulates the fate
of monocyte-derived cells in other inflammatory diseases
such as cardiovascular disease and liver fibrosis [13-15].
However, precisely how CX3CR1 regulates TAMs sub-
types in the tumor microenvironment remains unknown.
Our study showed that enhanced CX3CR1 expression was
correlated with the poor prognosis in human colon carcin-
oma. In mice lacking CX3CR1, the liver metastasis of colon
cancer cells was significantly inhibited. Mechanistically,Figure 1 Expression of CX3CR1 in tumor tissues. (A) Immunohistochem
normal colon tissues and human colon carcinoma. Histopathological differe
indicates tumor invasion depth. N indicates lymph node metastasis. M indi
Quantitative analysis of CX3CR1 expression in tumor sections at different h
and with or without recurrence 3 years after operation (n = 5-10 samples p
immunofluorescence analyses of macrophage and CX3CR1 expression in tu
from WT and CX3CR1−/− mice at 14 days after intrasplenic SL4 cells injectio
antibodies. Three independent experiments were performed. (×400 magnifCX3CR1 signaling was critical for survival of angiogenic
macrophages and promoting tumor angiogenesis. This
work highlights the function of CX3CR1 in the tumor in-
flammatory response and identifies CX3CR1 signaling as
the important player in the complex interactions between
tumor cells and the tumor microenvironment.
Results
Expression of CX3CR1 in TAMs is increased along with
colon carcinoma development
Because the treatment and prognosis of colorectal cancer
patients depends on the tumor grade (degree of primary
tumor differentiation) and tumor-node-metastasis stage
(how widespread the cancer is at the time of diagnosis), we
first measured the CX3CR1 expression levels in normal
colon tissues and human colon cancer tissue. As shown in
Figure 1A, CX3CR1 was rarely detected in normal tissues,
whereas CX3CR1 was observed in the inflammatory-
like cells located in carcinoma tissue. CX3CR1 expres-
sion was significantly elevated in poorly differentiated
colon carcinoma, which was much higher than that of
moderately differentiated or well-differentiated colon car-
cinoma (Figure 1A). The clinical colon carcinoma stagesical analysis of CX3CR1 or macrophage marker CD68 expression in
ntiation grade indicates well-, moderately- and poorly-differentiated. T
cates distant metastasis. (×200 magnification and Scale bars = 100 μm).
istologic grade (well, moderate and poor), different tumor stages (I-IV)
er group, with 10 fields per samples). **, P<0.01. (B) Double-color
mors. Tumor tissues of metastasized foci in the liver were obtained
n. The sections were immunostained with anti-F4/80 and anti-CX3CR1
ication and Scale bars = 50 μm).
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tumor into the submucosa, muscularis propria, or through
the wall of the colon, and by invasion to nearby lymph
nodes at stage III and to distant metastases in stage IV
tumors. CX3CR1 was expressed in a high percentage
of stage III and IV tumors (Figure 1A). Moreover, analysis
of CX3CR1 expression in primary tumors and formation of
metastases revealed that patients who had advanced clinical
stage disease, metastasis, or recurrent lesion within 3 years
showed increased CX3CR1 expression in colon cancer tis-
sue (Figure 1A). Thus, CX3CR1 expression is associated
with the aggressiveness of human colon cancer.
In addition, the advanced colon carcinoma tissues were
markedly and extensively infiltrated by CD68-positive
macrophages, particularly along the tumor cell-invasive
front; however, the number of macrophages in normal
colon tissues was low (Figure 1A). CX3CR1-positive cells
within the area colocalized with CD68-positive macro-
phages, indicating a high concordance of CD68 and
CX3CR1 expression in human primary colon carcinoma
during malignant progression.
To further analyze the expression of CX3CR1 in the
tumor stroma, we utilized a murine model in which
mouse colon cancer cells (SL4) were injected into the
spleen and tumors developed in the liver. Previous studies
have shown that SL4 cells form tumors in the liver of
100% of syngeneic mice when injected intrasplenically.
This model is not a pathological metastatic tumor model;
however, SL4 cells are a useful tool to study how injected
colon carcinoma cells seed and develop into a new micro-
environment in the liver [16]. Liver tumor sections were
immunostained with the macrophage marker F4/80 and
an anti-CX3CR1 antibody. Immunofluorescence staining
showed that CX3CR1 was abundantly expressed in macro-
phages in hepatic metastatic tumors of WT mice; as
expected, there was no CX3CR1 expression in CX3CR1−/−
control mice (Figure 1B). These results indicate that ex-
pression of CX3CR1 in TAMs is increased during malig-
nant progression, which might have predictive value in
determining tumor outcome.
CX3CR1 deficiency impairs the hepatic metastatic ability
of colon cancer cells
To investigate the role of CX3CR1 in tumor development of
colon carcinoma cells in the liver, we injected CX3CR1−/−
mice and WT controls with SL4 cells intrasplenically. The
SL4 cells generated tumors within the spleen (primary)
and liver (metastasis). Multiple hepatic tumor nodules, de-
tectable by gross inspection, were evident by 2 weeks.
Livers were isolated and the incidence of hepatic metasta-
sis was evaluated. Livers from CX3CR1−/− mice showed
significantly smaller tumor foci, fewer metastatic tumors,
and decreased tumor-occupied area compared with those
from tumor-bearing WT mice (Figure 2A).To further evaluate the anti-metastasis effect in
CX3CR1 deficiency, micrometastasis to livers were
quantified in H&E-stained sections. WT mice exhibited
massive and developed metastatic nodules in their livers,
whereas CX3CR1−/− mice had several small metastasis
nodules (Figure 2B). Histologic analysis showed that the
number of hepatic micrometastasis was significantly de-
creased in CX3CR1−/− mice compared with the number
in WT mice. These results indicate that CX3CR1 plays a
critical role in promoting metastasis.
CX3CR1 deficiency reduces macrophage accumulation in
metastatic tumors
The relative proportions of leukocytes that infiltrated into
hepatic metastatic tumors were analyzed and compared be-
tween CX3CR1−/− and WT mice. As shown in Figure 3A,
the proportion of CD45-positive leukocytes that infiltrated
into metastatic tumors was significantly decreased in
CX3CR1−/− mice compared to that in WT mice (9.61 ±
0.87% versus 19.16 ± 1.12% for CD45, P<0.01). In particu-
lar, the proportion of infiltrating CD45+F4/80+ cells in
metastatic tumors was significantly lower in CX3CR1−/−
mice than that in WT mice (31.22 ± 2.10% versus 51.79 ±
2.66% for CD45+F4/80+ cells, P<0.01; Figure 3A). Fur-
thermore, immunohistochemical staining of metastatic
foci further demonstrated that the expression of Mac-2
(a macrophage marker) was markedly decreased in
CX3CR1−/− mice relative to that in WT mice (Figure 3B).
Thus, CX3CR1 plays an important role in promoting
macrophage infiltration in metastatic tumors.
CX3CR1 deficiency enhances macrophage apoptosis in
metastatic tumors
To investigate the mechanism by which CX3CR1 pro-
motes macrophage infiltration into metastatic foci, we
analyzed macrophage apoptosis in metastatic tumors.
Both the number of TUNEL- and F4/80-positive (macro-
phage marker) cells was significantly increased in meta-
static tumors in CX3CR1−/− mice compared with those in
WT mice (Figure 4A). Moreover, we analyzed the role of
CX3CR1 on apoptotic pathways. As shown in Figure 4B,
CX3CR1 knockout significantly increased the Bax/Bcl-2
ratio in metastatic tumors compared with that in WT
mice. Similarly, caspase 3 activation was markedly unregu-
lated in the metastatic tumors of CX3CR1−/− mice versus
WT mice (Figure 4B). However, no alteration of FOXO3a
phosphorylation was detected in metastatic foci in either
CX3CR1−/− or WT mice (Figure 4B).
To understand the role of CX3CR1 in macrophage
survival during hepatic metastasis of colon cancer, we
cocultured macrophages derived from CX3CR1−/− or WT
mice with murine SL4 colon cancer cells in a 3D peptide
gel. A peptide gel was chosen because it more accurately
resembles the extracellular matrix milieu of carcinoma
Figure 2 CX3CR1 deficiency inhibits metastatic ability of colon cancer cells. (A) Gross examination of development of liver metastasized
tumor of colon cancer 14 days after intrasplenic injection of SL4 cells in WT and CX3CR1−/− mice. SL4 cells (1 × 106) were injected into the spleen
of WT and CX3CR1−/− mice. Mice were sacrificed at 14 days after tumor injection to determine the incidence of liver metastasis, the number of
metastasized foci in the liver, tumor weight and total tumor area represented as% of liver tissue. Data are mean ± SEM for n = 10 mice **, P<0.01.
(B) The analysis of micrometastasis was performed on paraffin-embedded sections with HE staining in metastasized foci after intrasplenic injection
of SL4 cells in WT and CX3CR1−/− mice. T, tumor tissue; N, normal liver tissue. (×100 magnification and Scale bars = 100 μm). Data are mean ± SEM for
n = 10 mice with 10 fields per animal. **, P<0.01.
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basement membrane-type extracellular matrix [17]. As
shown in Figure 4C, the number of both TUNEL- and F4/
80-positive (macrophage marker) cells was significantly in-
creased in CX3CR1−/− macrophages cocultured with SL4
cells, but not WT macrophages. Therefore, CX3CR1 is re-
sponsible for promoting macrophage survival within the
tumor microenvironment, which is typically associated
with TAMs that contribute to tumor development.
Expression of CX3CR1 in macrophages promotes
angiogenesis in metastatic tumors
We investigated whether the decreased metastatic ability
of tumor cells in CX3CR1−/− mice could be caused byinhibition of angiogenesis. Thus, we stained slices of tu-
mors of comparable size, grown either in WT or
CX3CR1−/− mice, with an anti-CD31 antibody (a marker
of endothelial cells). As shown in Figure 5A, the total
vessel area and size were significantly smaller in meta-
static foci grown in the livers of CX3CR1−/− mice than
those in WT mice. Immunohistochemistry and western
blot analysis showed that the levels of the proangiogenic
cytokines VEGF and TGF-β were significantly decreased
in metastatic liver tumors in CX3CR1−/− mice compared
with those in WT mice (Figure 5A and B). To further
explore the relationship between CX3CR1 expression in
macrophages and tumor angiogenesis, we assayed the
proangiogenic function of macrophages from metastatic
Figure 3 CX3CR1 deficiency reduces macrophages accumulation in metastasized tumor. (A) Leukocytes were gated with CD45
fluorescence vs side angle scatter (SS). Scatter plots are gated on CD45+ population cells. Macrophages (CD45+F4/80+ cells) were detected by flow from
metastasized foci in the liver after intrasplenic injection of SL4 cells in WT and CX3CR1−/− mice. Data represent the means ± SEM for n = 8 mice. **, P<0.01.
(B) HE staining and immunohistochemical analysis of macrophage infiltration in metastasized foci after intrasplenic injection of SL4 cells in WT and
CX3CR1−/− mice. Macrophage infiltration detected by anti-Mac-2 immunostaining. (×400 magnification and Scale bars = 50 μm). Quantitative analysis of
Mac-2 positive cells in metastasized foci sections. Data are mean ± SEM for n = 8 mice with 10 fields per animal. **, P<0.01.
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phages from metastatic tumors in CX3CR1−/− mice
expressed significantly less CCR2, VEGFR2, and
CXCR4 (proangiogenic markers) compared to WT
mice (40.72 ± 3.89% versus 75.78 ± 3.08% for CCR2,
P<0.01; 36.58 ± 3.97% versus 55.08 ± 4.13% for
VEGFR2, P<0.05; 39.04 ± 2.46% versus 70.78 ± 3.07%
for CXCR4, P<0.01; Figure 5C).
To further confirm the in vivo proangiogenic role of
CX3CR1 expression in macrophages, Matrigel plugs
containing WT or CX3CR1−/− macrophages were sub-
cutaneously implanted in WT or CX3CR1−/− mice. After
7 days, the mice were sacrificed and the plugs were
microscopically analyzed by staining the blood vessels
with an anti-CD31 antibody. As shown in Figure 5D,
plugs containing WT macrophages in WT mice were
well vascularized with well-formed and branched vessels,
whereas plugs containing CX3CR1−/− macrophages in
WT mice displayed poorly organized vessels. In addition,plugs containing WT macrophages in CX3CR1−/− mice
showed well-formed vessels compared to those contain-
ing CX3CR1−/− macrophages in CX3CR1−/− mice. Taken
together, these results suggested that CX3CR1 was ne-
cessary for TAMs-induced angiogenic responses during
tumor development.
Discussion
The chemokine receptor CX3CR1 plays an important
role in the development of numerous chronic inflamma-
tory diseases by modulating inflammatory responses,
particularly macrophage phenotype and function. As
cancer is a chronic inflammatory disease, it is recognized
that the inflammatory microenvironment plays a critical
role in tumor progression. Recent studies have demon-
strated that the monocyte/macrophage chemokine re-
ceptor CX3CR1 is essential for nascent microvessel
formation, structural integrity and maturation in Matrigel
and experimental plaque neovascularization models [18].
Figure 4 CX3CR1 deficiency increases macrophage apoptosis in metastasized tumor. (A) The TUNEL assay and immunofluorescence
analysis of macrophage apoptosis from metastasized foci after intrasplenic injection of SL4 cells in WT and CX3CR1−/− mice. Representative
micrographs show F4/80-positive (red), TUNEL-positive signal (green), nuclei (blue) in metastatic foci. The apoptotic index of macrophages
was assessed as the percentage of apoptotic TUNEL+F4/80+ cells to the total number of F4/80+ cells. Scale bars =40 μm. Data are mean ±
SEM for n = 8 mice with 10 fields per animal. **, P<0.01. (B) Western blot analysis of the protein levels of Bax, Bcl-2, phospho-FOXO3a,
FOXO3a and activate caspase3 from metastasized foci in the liver after intrasplenic injection of SL4 cells in WT and CX3CR1−/− mice. GAPDH
was used as a loading control. Quantitative analysis of Bax/ Bcl-2 ratio, phospho-FOXO3a/FOXO3a ratio and activate caspase3 expression in
metastasized foci from WT and CX3CR1−/− mice. Data are mean ± SEM for n = 8 mice. **, P<0.01. NS, not significant. (C) WT or CX3CR1−/−
macrophages were co-cultured with SL4 cells in peptide gels and then underwent TUNEL assay and immunofluorescence analysis of
macrophage apoptosis by staining with F4/80 antibody. The nucleus was stained with DAPI. Representative micrographs show F4/80-posi-
tive (red), TUNEL-positive signal (green), nuclei (blue) in coculture. The apoptotic index of macrophages was assessed as the percentage
of apoptotic TUNEL+F4/80+ cells to the total number of F4/80+ cells from 10 randomly selected regions. Scale bars = 25 μm. Data are
mean ± SEM of 3 independent experiments. **, P<0.01. Mφ indicates macrophages.
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tion, the mechanism by which CX3CR1 regulating macro-
phage function contributing to tumor development
remains unclear. In the present study, especially we dem-
onstrated the role of CX3CR1 in regulating tumor inflam-
matory microenvironment. The present work elucidated
CX3CR1 mediates survival of macrophage, promoting
angiogenesis leading to tumor metastasis.
Tumor development is a complex event that involves
not only tumor cells but also the surrounding stroma.
The tumor microenvironment and neoplastic cells act in
concert to promote the growth and progression of the
tumor mass [4]. In the stroma of several tumor types, a
critical role has been demonstrated for TAMs, whichrepresent the major inflammatory component [5,19]. Ex-
perimental models have demonstrated that the lack of
macrophage recruitment to the tumor site results in de-
creased tumorigenic ability [20,21], and clinical evidence
has shown a correlation between high TAMs content in-
side of tumors and a poor prognosis [19]. Along with
these previous results, our study showed that macro-
phage infiltration was negatively associated with human
colon carcinoma prognosis (Figure 1A).
TAMs are differentiated mononuclear phagocytic lineage
cells that are characterized by specific phenotypic charac-
teristics and the expression of particular markers, and
have been implicated in tumor growth, invasion, and
angiogenesis in the tumor microenvironment [6,22-25].
Figure 5 CX3CR1 deficiency blocks angiogenesis through inhibiting angiogenic macrophage in tumor. (A) The area of vessels and the
expression of pro-angiogenesis cytokines were evaluated by immunohistochemical analysis with anti-CD31, anti-VEGF or anti-TGF-β antibodies.
(×200 magnification and Scale bars = 100 μm). Quantitative analysis of CD31, VEGF and TGF-β expression in metastasized foci sections. Data are
mean ± SEM for n = 8 mice with 10 fields per animal. **, P<0.01. (B) Western blot analysis of the protein levels of VEGF and TGF-β in metastasized
foci. GAPDH was used as a loading control. Quantitative analysis of VEGF and TGF-β expression in metastasized foci from WT and CX3CR1−/− mice.
Data are mean ± SEM for n = 8 mice. **, P<0.01. (C) Scatter plots gated on CD45+ cells, angiogenic markers CCR2, VEGFR2 and CXCR4 in CD11b+
cells were determined from metastasized foci in the liver after intrasplenic injection of SL4 cells in WT and CX3CR1−/− mice. Data are mean ± SEM
for n = 8 mice. *, P<0.05; **, P<0.01. (D) Matrigel plugs containing either WT or CX3CR1−/− macrophages were subcutaneously implanted in WT or
CX3CR1−/− mice for 7 days. Evaluation of blood vessels with anti-CD31 antibody. (×200 magnification and Scale bars = 100 μm). Data are mean ±
SEM of 3 independent experiments with 10 fields per sample. **, P<0.01. Mφ indicates macrophages.
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owing to its differential expression; this surface molecule
plays an important role in the initiation and progression of
inflammation [9-12,26] and is upregulated in inflammatory
diseases [8,27-31]. However, the role of CX3CR1 in the de-
velopment of the tumor microenvironment remains un-
clear. In this study, we observed that colon carcinoma
patients at more advanced clinical stages, those with lymph
node or liver involvements, and those who had recurrence
within 3 years displayed markedly higher CX3CR1 ex-
pression levels (Figure 1A). The association between the
increased expression of CX3CR1 and clinical stage, me-
tastasis, and recurrence suggests its potential utility as
an independent or supplementary biomarker in theprediction of tumor prognosis. Furthermore, we found
that development of metastatic liver tumors was substan-
tially inhibited in CX3CR1−/− mice as compared with WT
littermates, suggesting the critical role of CX3CR1 expres-
sion in TAMs-mediated tumor development.
The chemokine receptor CX3CR1 is the only known
corresponding CX3CL1 receptor. CX3CR1 is primarily
expressed on circulating monocytes, tissue macrophages,
and tissue dendritic cell populations but is also expressed
on T cell and natural killer cell subsets [8]. In this study,
we showed that the absence of CX3CR1 reduced the pro-
portion of macrophages that infiltrated into the metastatic
foci (Figure 2). CX3CR1 is required for monocyte survival
and differentiation in atherosclerosis and liver fibrosis
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cantly promoted macrophage apoptosis in the tumor
microenvironment both in vivo and in vitro (Figure 4),
which indicates that CX3CR1 deficiency inhibits macro-
phage infiltration in metastatic tumors through induction
of macrophage apoptosis. Studies have demonstrated that
apoptosis is regulated by a complex network of signaling
pathways that control the expression and degradation of
key molecules, including Bcl-2 family proteins and cas-
pases [32]. As expected, CX3CR1 promoted the survival
of macrophages in metastatic tumors through suppression
of the proapoptotic pathway (Figure 4B).
In most tumors, there is dramatic enhancement of vas-
cular density from the benign-to-malignant transition, a
process referred to as the angiogenic switch. These data
strongly argue for a role of the angiogenic switch in regu-
lating malignant transition and for macrophages as im-
portant players in vascular remodeling as tumors progress
to late carcinoma stages [20,33-35]. This effect seems to
be the most likely cause of reduced tumor growth and me-
tastasis after the macrophage depletion observed in these
transplants models, as tumor progression is closely
dependent on rapid angiogenesis. We therefore won-
dered if CX3CR1 could play a role in tumor angio-
genesis. Our results showed that CX3CR1 deficiency
impaired tumor angiogenesis in metastatic foci (Figure 5A
and B). Furthermore, our data demonstrated that CX3CR1
deficiency suppressed macrophage expression receptors
CCR2, VEGFR2, and CXCR4 (cell surface markers of an-
giogenic macrophages) [6] in hepatic metastatic
tumors (Figure 5C). We further confirmed that
CX3CR1 expression in macrophages was required for
angiogenesis in vivo, as its deficiency resulted in
the presence of smaller vessel density and vessel area
(Figure 5D). Taken together, these data suggested that
CX3CR1 contributed to macrophages survival and pro-
moting angiogenesis in the tumor microenvironment.
Conclusions
In summary, we identified the role for CX3CR1 in mac-
rophages that can promote tumor metastasis and is as-
sociated with poor cancer prognosis by contributing to
angiogenic macrophage survival. As numerous attempts
are ongoing to target the tumor stroma, we propose
CX3CR1 as a potential molecular target for antiangio-
genic and antimetastatic cancer therapy.
Methods
Antibodies and reagents
The antibodies for CX3CR1, CD68, CD31, VEGF, TGF-
β, Mac-2, GAPDH, and IgG were from Santa Cruz Bio-
technology (Santa Cruz, CA, USA); the antibodies for
phospho-FOXO3a, FOXO3a, Bax and Bcl-2 were from
Cell Signaling Technology (Beverly, MA, USA); theantibodies for F4/80 and A-Caspase3 were from Abcam
(Cambridge, MA, USA); and ChemMate TM EnVision Sys-
tem/DAB Detection Kits were from Dako (Glostrup,
Denmark). Antibodies for PerCP/Cy5.5-conjugated CD45.2,
phycoerythrin (PE)-conjugated F4/80, APC-conjugated
CD11b and isotype control were from Biolegend (San
Diego, CA, USA). Antibodies for PE-conjugated CCR2,
PE-conjugated VEGFR2, PE-conjugated CXCR4 and iso-
type control were from R&D Systems (Minneapolis,
MN, USA). DeadEnd™ fluorometric TUNEL system was
from Promega (Madison, WI, USA).
Animals
CX3CR1 knockout (CX3CR1−/−) mice and wild-type
(WT) littermates were used for all experiments. CX3CR1
knockout (CX3CR1−/−) mice were harbored a target re-
placement of the CX3CR1 gene by a GFP gene [36].
CX3CR1−/− mice were obtained from the Jackson La-
boratory and maintained in a Specific Pathogen-Free at-
mosphere at the Beijing Anzhen Hospital affiliated to
the Capital Medical University, China. The investigations
conformed to the US National Institutes of Health Guide
for the Care and Use of Laboratory Animals (publication
no. 85–23, 1996) and were approved by the Animal Care
and Use Committee of Capital Medical University.
Human colon carcinoma specimens
The specimens from 30 cases of human colon carcinoma
tissue/adjacent normal colon tissues and the clinicopath-
ologic data were obtained from the Second Affiliated
Hospital to Nanchang University gastrointestinal tumor
bank. The specimens were isolated at the time of sur-
gery, formalin-fixed and paraffin-embedded, and stained
with hematoxylin and eosin, then examined by 2 experi-
enced pathologists. The clinicopathologic stage was de-
termined according to the TNM classification system of
the International Union against Cancer. Human speci-
mens use for research had been approved by the Second
Affiliated Hospital to Nanchang University Research
Ethics Committee.
Tumor model
A highly metastatic murine colon adenocarcinoma cell
line, colon SL4, was used for the in vivo experiments
[16]. SL4 cells were derived from C57BL/6 mice on the
same background as the CX3CR1 deficient mice and
WT control mice. SL4 cells were maintained in 1:1 mix-
ture of Dulbecco’s modified Eagle’s medium and Ham’s
F-12 medium (DMEM/F12) containing 10% heat-
inactivated fetal calf serum (FCS) in a humidified atmos-
phere of 95% air and 5% CO2 at 37°C. For in vivo model,
after anaesthetizing mice, a transverse incision in the left
flank was made, exposing the spleen, then 1.0 × 106 SL4
tumor cells in 100 μl DMEM/F12 medium were
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14 days after inoculation, mice were sacrificed, and the
tissues were processed as described below. After the ini-
tial dissection, the left ventricle was flushed by puncture
with 40 ml normal saline to remove blood samples. The
spleen and liver were removed, wet spleen and liver
weights were measured, and the incidence of liver tumor
development was examined.
Histology and immunohistochemistry
Livers in mice were fixed for 24 hrs with 10% buffered for-
malin before embedding in paraffin. Serial sections of
5 μm thick were obtained for histologic analysis. Hema-
toxylin&eosin (HE) staining involved standard procedures.
For immunohistochemistry, sections were incubated
with the primary antibody for CX3CR1(1:200), CD68
(1:200), CD31(1:200), VEGF(1:200), TGF-β(1:200), or
Mac-2(1:200), then incubated with the Dako Chem-
Mate™ EnVision System (Dako, Glostrup, Denmark) for
30 mins. Staining was visualized with use of diamino-
benzidine and counterstaining with hematoxylin. Nega-
tive controls were omission of the primary antibody,
non-immune IgG or secondary antibody only; in all
cases, negative controls showed insignificant staining.
Images were captured with use of a Nikon Labophot 2
microscope equipped with a Sony CCD-Iris/RGB color
video camera attached to a computerized imaging sys-
tem and analyzed by use of ImagePro Plus 3.0 (ECLIP-
SE80i/90i; Nikon, Japan) with blinding to treatment. The
expression of CX3CR1, CD68, CD31, VEGF, TGF-β, or
Mac-2 was calculated as proportion of positive area to
total tissue area for all measurements of the section.
For double immunofluorescence, tumors were excised
and fixed in 4% paraformaldehyde for 2 hrs, then dehy-
drated with 30% sucrose/PBS and frozen in compound.
Frozen tissue sections, 7 μm, were permeabilized and
blocked with 0.1% Triton X-100, 0.2% bovine serum al-
bumin, and 5% normal donkey serum in PBS, then incu-
bated with the primary antibodies F4/80 (1:100) and
CX3CR1 (1:100)overnight at 4°C, then FITC or TRITC-
conjugated secondary antibody (Jackson Immuno Re-
search Laboratories, West Grove, PA, USA) at room
temperature for 1 hr in the dark, and coverslipped with
DAPI-containing mounting medium.
TUNEL staining
Identification of apoptotic cells was performed using
TUNEL system Kit (Promega). Briefly, frozen slides were
permeabilized using 0.1% solution of Triton X-100 in so-
dium citrate. Consequently, slides were incubated with
TUNEL reaction mixture for 1 hr at 37°C. To allow detec-
tion of apoptotic macrophages, frozen sections were in-
cubated with the primary antibodies for F4/80 (1:100) at
4°C overnight and then with TRITC-conjugated secondaryantibody (Jackson ImmunoResearch Laboratories) at
room temperature for 1 hr. Nuclei were stained with
DAPI (Invitrogen). The apoptotic index of macrophages
was assessed as the percentage of apoptotic TUNEL+ F4/
80+ cells to the total number of F4/80+ cells.
Flow cytometry
For extracellular staining of immune markers, single-cell
suspensions were prepared by mechanical dispersion
and enzymatic digestion of tumor tissues as described
[17]. Briefly, tumor tissues were cut into multiple small
cubes and digested in an enzyme mixture for 45 mins at
37°C. The cell suspension was centrifuged and preincu-
bated with Fc-γ block antibody (anti-mouse CD16/32;
Pharmingen, San Diego, CA, USA) to prevent nonspe-
cific binding. Cell staining involved different combina-
tions of fluorochrome-coupled antibodies to CD45, F4/
80, CD11b, CCR2, VEGFR2 or CXCR4 for 30 mins
at room temperature in the dark. Fluorescence data were
collected by use of an EPICS XL flow cytometer (Beckman
Coulter) and analyzed by use of Cellquest (Beckman).
Fluorescence minus one (FMO) controls were included to
determine the level of nonspecific staining and autofluo-
rescence associated with subsets of cells in each fluores-
cence channel.
Western blotting
Protein extracts were were diluted with loading buffer and
separated by electrophoresis on 10% SDS-polyacrylamide
gels before transfer to nitrocellulose membranes. The
membranes were blocked in Odyssey blocking buffer
(LI-COR Bioscience, Lincoln, NE) at room temperature
for 1 hr, then incubated at 4°C overnight with primary
antibody: Bax (1:500), Bcl2 (1:500), p-Foxo3a (1:800),
Foxo3a (1:800), A-caspase3 (1:800) or GAPDH (1:1000).
The membranes were washed and incubated with fluores-
cent secondary antibodies (Alexa Fluor 680 or IRDye 800,
Rockland Immunochemicals, Gilbertsville, PA, US) for
1 hr at room temperature at 1:5000, blots were analyzed
with the Odyssey infrared imaging system and Odyssey
software.
Co-culture macrophages with tumor cells in three-
dimensional peptide gel
Macrophages were isolated from tibias and femurs of 8-
week-old WT and CX3CR1−/− mice as previously de-
scribed in our lab [17]. Three-dimensional peptide gel
co-culture was also as described [17]. Macrophages and
SL4 cells were mixed at a ratio of 1:2 in peptide gel at a
final peptide gel concentration of 3%. Peptide gel co-
culture was maintained in DMEM containing 10% FCS
at 37°C in a humidified atmosphere containing 5% CO2.
At 48 hrs after co-culture, peptide gel cultures were
fixed in 4% paraformaldehyde in PBS for 15 mins at
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zen sections, 7 μm, of peptide gel cultures were treated
with 0.15 M glycine in PBS at 4°C overnight to reduce
autofluorescence.
Matrigel plugs
700 μl of Matrigel (Becton Dickinson) was injected sub-
cutaneously in the ventral area in WT or CX3CR1−/−
mice. Matrigel plugs contained 5 × 105 WT or CX3CR1−/−
macrophages. Plugs containing PBS were used as a
negative control, whereas plug containing 100 ng/ml
bFGF (R&D Systems), a known angiogenic factor, was
used as a positive control. Each experimental condition
was analyzed in triplicate. 7 days after plug implant-
ation, plugs were collected, immediately fixed in 10%
buffered formalin. Identification of angiogenesis was
performed by immunohistochemistry with the primary
antibody against CD31.
Statistics
Data analysis involved use of GraphPad software
(GraphPad Prism version 5.00 for Windows, GraphPad
Software). Results are expressed as mean ± SEM. Differ-
ences were analyzed by t test or ANOVA, and results
were considered significant at a P<0.05.
Abbreviation
TAMs: Tumor-associated macrophages; TGF: Transforming growth factor;
VEGF: Vascular endothelial growth factor; CXCR: Chemokine (C-X-C motif)
receptor; CCR: C-C chemokine receptor; VEGFR: Vascular endothelial growth
factor receptor.
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